Is There a Generic for Vevye?

No. The Orange Book lists no active FDA-approved generic (ANDA) for Vevye (cyclosporine). The Orange Book shows its last listed patent expires April 1, 2042 and its last listed exclusivity ends May 30, 2026.

Run it in Rivvi

Map Vevye and your other top fills to their generics

Every strength in RxNorm, with brands that have no generic flagged.

Build the map

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Vevye products in the Orange Book

Vevye products and approved generics
Form and route	Strength	Brand status	Brand TE	Active generics	Generic TE codes
solution, ophthalmic	0.1%	Marketed (Rx)	None	0	None

NDA 217469, held by HARROW EYE LLC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.

Vevye patents

Patents listed for Vevye
Patent	Expires	Covers	Use code	NDA
8614178	December 13, 2030	Drug product	None	217469
12496326	September 29, 2036	Method of use	U-3627	217469
10813976	September 22, 2037	Drug product	None	217469
11413323	October 11, 2039	Method of use	U-3627	217469
12059449	April 1, 2042	Drug product	U-1483	217469

Vevye exclusivity

Exclusivity listed for Vevye
Code	Meaning	Expires	NDA
NP	New product	May 30, 2026	217469

Vevye NDC codes

82667-900

Questions

Is there a generic for Vevye?

No. The Orange Book lists no active FDA-approved generic (ANDA) for Vevye (cyclosporine). The Orange Book shows its last listed patent expires April 1, 2042 and its last listed exclusivity ends May 30, 2026.

What is the generic name for Vevye?

The active ingredient in Vevye is cyclosporine, per the FDA Orange Book.

When does the Vevye patent expire?

The last patent listed for Vevye in the Orange Book expires April 1, 2042. A listed patent expiry date is not a generic launch date.

What does a therapeutic equivalence code mean?

In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.